Keeping pace with the ever-changing life sciences industry, Morrison Foerster stays on top of the trends and political, legal, and economic drivers to support striking the balance between innovative discovery and purposeful business planning to assure our clients continued success. MoFo Life Sciences shares timely legal and business insights and in-depth analyses on trends and the complex technologies at the heart of the global pharmaceutical, biotechnology, diagnostics, medical devices, digital health, and AgTech fields.Learn more about our <a href="https://www.mofo.com/capabilities/life-sciences-healthcare" target="_self">Life Sciences practice</a>.<h2 dir="ltr">ABOUT MORRISON FOERSTER</h2>Morrison Foerster is a leading global law firm that transforms complexity into advantage for its clients. Our clients include some of the largest financial institutions, banks, consulting and accounting firms, and Fortune 100, technology, and life sciences companies. Highlighting the firm’s commitment to client service, leadership in market-changing deals and impact litigation, and values-based culture, Morrison Foerster has been repeatedly recognized as one of the top 10 firms on The American Lawyer’s A-List. Year after year, the firm receives significant recognition from Chambers and The Legal 500 across their various guides, including Global, USA, Asia‑Pacific, Europe, UK, Latin America, and FinTech Legal. Our lawyers passionately care about delivering legal excellence while living our values. Morrison Foerster has a long-standing commitment to creating a culture that respects and celebrates differences, while providing an inclusive environment. The firm has achieved Mansfield Certification Plus since 2018 as a result of successfully reaching at least 30 percent women, communities of color, and LGBTQ+ lawyer representation in a notable number of current leadership roles and committees. The firm also has a long history of commitment to the community and society through providing pro bono legal services, including litigating for civil rights and civil liberties, improving public education and fostering the wellbeing of children, advocating for veterans, promoting international human rights, enforcing the right to asylum, and safeguarding the environment.

Social

Search

Subscribe

Life Sciences and Healthcare Group

Life Sciences Podcast

Patent Counseling + Prosecution

FDA Regulatory + Life Sciences Compliance

FDA + Healthcare Regulatory and Compliance 

Life Sciences Transactions + Licensing

Resources

Editors

230315-new-mofo-life-sciences-logo.jpg

Dr. Meghan Poon counsels clients on patent preparation and prosecution, portfolio strategy, and IP due diligence in the areas of biotechnology and biologics. She has significant experience in diverse technologies including antibodies, cell therapies, gene therapies, diagnostics, and gene-edited plants. She represents clients ranging from large international pharmaceutical companies to midsized companies, startups, and universities.Meghan has filed numerous Patent Term Extension applications to secure additional term for her clients’ patents, which cover FDA-approved products. In addition, Meghan has extensive experience addressing complex obviousness-double patenting and subject matter eligibility issues impacting her clients’ patent portfolios. Meghan also represents clients in both investor-side and target-side due diligence, in deals from seed funding to initial public offerings.Prior to law school, Meghan attended graduate school at the University of California, Los Angeles, where she received a Ph.D. in biological chemistry based on her work on protein-protein and protein-DNA interactions at a molecular level. Meghan is the author of several scientific publications and has presented her research at international conferences.Meghan received her J.D. from the University of Southern California Law School and spent a year as a visiting student at Santa Clara University, where she focused on intellectual property.

poon_meghan_blog_150x150.png

poon_meghan_common_640x280.jpg

poon_meghan_heroretina_2700x1160.jpg

poon_meghan_mobileretina_750x1040.jpg

poon_meghan_social_600x600.jpg

Partner

Dr. Meghan Poon counsels clients on patent preparation and prosecution, portfolio strategy, and IP due diligence in the areas of biotechnology and biologics. She has significant experience in diverse technologies including antibodies, cell therapies, gene therapies, diagnostics, and gene-edited plants.

Meghan Poon

Wolfgang advises clients on contentious and non-contentious matters involving their most valuable intellectual property assets in life sciences, digital, and high-tech industries.His subjects of focus include research and development collaborations, complex licensing agreements, and other technology transactions, as well as know-how protection strategies, and employee invention law. He also has substantial experience in litigating patents, trademarks, and other intellectual property assets, often in a multijurisdictional context. In addition, Wolfgang and his team frequently clear trademarks and ad campaigns and prosecute trademark applications.Wolfgang is co-editor of our <a href="https://lifesciences.mofo.com/" dir="ltr" target="_blank">MoFo Life Sciences Blog</a>.Wolfgang is a partner of Morrison Foerster based in our German office in Berlin.<h4 dir="ltr">Representative Transactional Matters</h4><ul dir="ltr"><li>U.S.-based BioTech fund on various research collaborations and other transactions with German start-ups or research institutions.</li><li>Negotiate multimillion-euro strategic partnership between two AgTech leaders concerning the development and commercialization of pest-resistant transgenic traits.</li><li>Craft global multi-million collaboration regarding AI-powered robotic MaaS.</li><li>UK-based digital health company on product roll-out of RPM applications in Germany; coordinate international expansion.</li><li>Advise numerous German start-ups on their U.S. expansion.</li><li>Draft diverse global patent and know-how license agreements in the areas of AgTech and life sciences—including gene licensing and licensing of genome editing technologies (e.g., CRISPR)—and medical devices; draft correlating supply and distribution agreements.</li><li>Structure IP rights in connection with joint ventures and other M&A transactions, including the carve-out of a patent-heavy semiconductor business comprising nine jurisdictions into a German–U.S. joint venture.</li><li dir="ltr">Advise on government-funded, multi-partner R&D projects and/or R&D projects with academic institutions, as well as on employee invention law.</li></ul><h4 dir="ltr">Representative Contentious IP Matters</h4><ul dir="ltr"><li>Lead counsel in an international dispute between software companies on rights and obligations following termination of a multi-million licensing and distribution arrangement; coordinate local counsel.</li><li>Defend Japanese chip manufacturer in high-profile SEP-litigation; advise on global settlement arrangement.</li><li>Represent leading internet retailer in patent infringement and concurrent invalidity proceedings in the context of a multijurisdictional dispute concerning touch-screen technology.</li><li>Represent diverse pharmaceutical and life sciences companies in national and cross-border patent infringement proceedings and other technology-related disputes, including preliminary injunctions as well as pre‑trial discovery and inspection proceedings, concerning, inter alia, drug-coating technologies, toner cartridges, medicinal gases, transgenic plants, and vaccines.</li><li dir="ltr">Conduct trademark, copyright, and false advertising litigation, including, most notably, a high-profile trademark litigation for a German bank, and a nine-country cross-border trademark litigation involving a famous pharmaceutical brand.</li></ul>

Dr. Wolfgang Schönig berät Mandanten zum Schutz des geistigen Eigentums sowohl in streitigen als auch nichtstreitigen Angelegenheiten, mit einem besonderen Fokus auf die IP-rechtliche Beratung von Unternehmen aus den Bereichen Life Sciences, Digitalwirtschaft und High-Tech.Zu seinen Beratungsschwerpunkten gehören Forschungs- und Entwicklungskooperationen, komplexe Lizenzvertragsgestaltungen und andereTechnologie-Transaktionen, sowie Know-how-Schutz-Strategien und das Arbeitnehmererfinderrecht. Er verfügt zudem über umfangreiche Prozesserfahrung zur Durchsetzung von Patenten, Marken- und anderen IP-Rechten, häufig auch in einem grenzüberschreitenden Kontext. Darüber hinaus bewertet Dr. Wolfgang Schönig zusammen mit seinem Team regelmäßig die Rechtskonformität von Werbekampagnen, prüft die Verfügbarkeit von Marken und entwickelt entsprechende Anmeldestrategien.Dr. Wolfgang Schönig ist Co-Editor des Life Sciences Blogs von Morrison Foerster.Er hat seinen Doktortitel an der Heinrich-Heine-Universität Düsseldorf und seinen LL.M. an der Fordham School of Law in New York erworben, jeweils mit Schwerpunkt im gewerblichen Rechtsschutz. Seinen MBA-Abschluss erhielt er von der European University in Barcelona.Dr. Wolfgang Schönig ist Partner des deutschen Büros von Morrison Foerster in Berlin.<h4 dir="ltr">Repräsentative Transaktionen</h4><ul><li dir="ltr">BioTech-Fonds mit Sitz in den USA bei verschiedenen Forschungskooperationen und anderen Transaktionen mit deutschen Start-ups oder Forschungseinrichtungen</li><li dir="ltr">Verhandlung einer hochvolumigen strategischen Partnerschaft zwischen zwei Technologieführern im Bereich Crop Science betreffend der Entwicklung und Kommerzialisierung von bestimmten Resistenzen</li><li dir="ltr">Gestaltung einer globalen Multi-Millionen-Zusammenarbeit für KI-gestützte Roboter</li><li dir="ltr">Ein in Großbritannien ansässiges Unternehmen für digitale Gesundheit bei der Markteinführung von RPM-Anwendungen in Deutschland; Koordination der internationalen Expansion</li><li dir="ltr">Beratung zahlreicher deutscher Start-ups bei deren US-Expansion</li><li dir="ltr">Strukturierung und Verhandlung diverser Patent- und Know-How-Lizenzen in den Bereichen Ag Tech und Life Sciences – einschließlich Fragen zu genome editing wie CRISPR-Medizingeräte, sowie Gestaltung von Softwarelizenzverträgen und Erstellung korrespondierender Liefer- und Vertriebsvereinbarungen</li><li dir="ltr">Strukturierung von IP-Rechten im Zusammenhang mit Joint Ventures und anderen M&A-Transaktionen, darunter die Koordination eines neun Länder umfassenden IP Carve-Outs im Rahmen eines Halbleiter-JVs</li><li dir="ltr">Beratung zu staatlich geförderten Multi-Partner F&E-Projekten und/oder F&E-Projekten mit akademischen Einrichtungen sowie zum Arbeitnehmererfindungsrecht</li></ul><h4 dir="ltr">Repräsentative IP-Streitigkeiten</h4><ul><li dir="ltr">Lead Counsel in einem internationalen Rechtsstreit zwischen Softwareunternehmen über Rechte und Pflichten nach Beendigung einer millionenschweren Lizenz- und Vertriebsvereinbarung; Koordinierung der lokalen Anwälte</li><li dir="ltr">Verteidigung eines japanischen Chipherstellers in einem prominenten Streitfall bezüglich Standardessentieller Patente (SEP); Beratung zu einer globalen Vergleichsregelung</li><li dir="ltr">Verteidigung einer führenden Internetplattform gegen Ansprüche eines Patenttrolls wegen vermeintlicher Verletzung von Patent bezüglich Touchscreen-Technologie sowie korrespondierende US-Streitigkeiten</li><li dir="ltr">Vertretung von Pharma- und Life Science-Unternehmen in nationalen und grenzüberschreitenden Patentverletzungsverfahren und anderen technologiebezogenen Streitigkeiten, einschließlich einstweiliger Verfügungsverfahren und vorprozessualer Beweissicherungs- und Besichtigungsverfahren, unter anderem in Bezug auf Arzneimittelbeschichtungstechnologien, Tonerkartuschen, medizinische Gase, transgene Pflanzen und Impfstoffe</li></ul>

schonig_wolfgang_blog_150x150.png

schonig_wolfgang_common_640x280.jpg

schonig_wolfgang_heroretina_2700x1160.jpg

schonig_wolfgang_mobileretina_750x1040.jpg

schonig_wolfgang_social_600x600.jpg

Wolfgang Schönig is a partner of Morrison Foerster (International) LLP based in our German office in Berlin. His practice specialty is advising on IP aspects relative to transactions in, among others, the life sciences, AgTech and pharmaceuticals industry, as well as legal representation in IP disputes. Wolfgang is specialized in research and development collaborations, complex licensing agreements, technology acquisitions, know-how protection strategies, and employee invention law.

Wolfgang Schönig focuses his practice on IP aspects relative to transactions in the digital, telecoms, high tech, life sciences, and pharmaceuticals industry, as well as legal representation in IP disputes.

Wolfgang Schönig advises clients on IP aspects relating to transactions in, among others, the life sciences, AgTech and pharmaceuticals industry, as well as legal representation in IP disputes. His additional focus areas include research and development collaborations, complex licensing agreements, technology acquisitions, know-how protection strategies, and employee invention law.

Wolfgang Schönig

favicon.ico

favicon-16x16.png

favicon-32x32.png

apple-touch-icon.png

MoFo Favicons

MoFo Life Sciences shares timely legal and business insights and in-depth analyses on trends and the complex technologies at the heart of the global pharmaceutical, biotechnology, diagnostics, medical devices, digital health, and AgTech fields.

life-sciences-featured-image.jpg

life-sciences-featured-image

Announcements

Welcome to Mofo Life Sciences

Blog - Terms of Use

Cookies

Blog - Privacy Policy

Blog - Blog Disclaimer

Blog - Attorney Advertising

morrison-foerster-blog-logo.png

Brings together legal insights and in-depth analyses on trends and complex issues shaping the global technology industry.

MoFo Tech Blog

MOFO TECH

Equips our clients with the most up-to-date and relevant information on employment and labor law issues.

Employment Law Commentary

EMPLOYMENT LAW COMMENTARY

Stay on top of emerging issues and stay informed of developments related to the law and business of social media.

Socially Aware

SOCIALLY AWARE

In-depth analysis of developments and trends impacting government contracting.

Government Contracts Insights Blog

GOVERNMENT CONTRACTS INSIGHTS

Provides insights and reports on the most current class actions lawsuits and product liability issues that affect consumer-facing companies.

Class Dismissed Blog

CLASS DISMISSED

MoFo Life Sciences

  Linkedin

MoFo LinkedIN

Life Sciences Blog - RSS

Stay Connected

Never miss a post from MoFo Life Sciences. Enter your email below to stay up-to-date.

Because No One is Immune to the Law

Morrison Foerster - Footer

Blogs -  Home Button

Home

Blog - Topics

Agtech

Antitrust

Asia

Bioinformatics

Biotech

Blockchain

Cell + Gene Therapy

CFIUS

Corporate + Venture Capital

COVID-19

Data Analytics

Digital Health

Employment

European Union

Financing

Global

Healthcare

Intellectual Property

Licensing + Commercial

Litigation

Medical Devices + Diagnostics

Pharma

Privacy + Data Security

Product Liability + Class Action

Rare Disease

Regulatory

Startup

United Kingdom

United States

Topics

Blog - Editors

Blog - About

About

Blog - Subscribe

Meghan McLean Poon Ph.D.

More

Front-of-pack, Front-of-mind

FDA Releases Draft Guidance on Evaluating the Risk and Credibility of AI Used in Establishing Drug and Device Safety, Effectiveness, and Quality

What is “Healthy?” Are Fats In?

Stop-Gap Spending Bill Provision Takes Aim at Biologics Patent Litigation

An InSECURE Future: Court Ruling Guts USDA Regs on Genetically Engineered Plants

LinkedIN

*UPDATE DECEMBER 19, 2024:* USDA-APHIS RESTORES LEGACY PERMITTING AND “AM I REGULATED” PROCESSES FOR GE ORGANISMSUSDA Animal and Plant Health Inspection Service (APHIS) <a href="https://www.aphis.usda.gov/news/program-update/aphis-restarts-permitting-am-i-regulated-processes-products-biotechnology" target="_blank">announced</a> on December 19, 2024, that it is restoring its legacy framework for permitting and deregulation of genetically engineered (GE) organisms that was in place before 2020. The move comes in response to the December 2, 2024, ruling by the U.S. District Court for the Northern District of California that struck down core APHIS regulations on GE organisms established by the agency in 2020. See our recent blog post (below) for a detailed discussion of the December 2 ruling and its potential implications.Under the now-current legacy framework, a GE organism is assessed with a greater focus on the processes used to create it, while the now-vacated 2020 regulations focused more on the potential plant pest risk of the final modified organism as a product. The now-effective legacy regulations also lack the categorical exemptions included in the vacated 2020 rule. However, APHIS maintains as of this writing that responses to <a href="https://www.aphis.usda.gov/biotechnology/am-i-regulated" target="_blank">requests for confirmation</a> of exemption that APHIS issued before Dec. 2, 2024, remain valid.While there are no longer categorical exemptions from APHIS regulation, APHIS is reestablishing the <a href="https://www.aphis.usda.gov/biotechnology/am-i-regulated" target="_blank">“Am I Regulated?”</a> process (also known as “AIR”), which allows developers to seek a determination of nonregulated status. This status will exempt the GE organism from regulation under <a href="https://www.ecfr.gov/on/2019-12-31/title-7/subtitle-B/chapter-III/part-340?toc=1" target="_blank">7 CFR part 340 (2019)</a>, including its permit requirements, as it had prior to the 2020 rule.The return to the legacy framework also reinstates the <a href="https://www.ecfr.gov/on/2019-12-31/title-7/subtitle-B/chapter-III/part-340/section-340.3" target="_blank">notification system</a>, a streamlined alternative to permitting for eligible regulated organisms considered to pose a lower plant pest risk.APHIS stated that it will resume issuing permits under the legacy framework within the coming days and will provide additional information in the coming weeks on resuming the notification process. MoFo is closely monitoring developments and is available to assist clients affected by these regulatory changes.<hr class="divider">ORIGINAL POST (DECEMBER 6, 2024):In a decision that raises significant questions about the future oversight of genetically engineered (GE) plants in the United States, the U.S. District Court for the Northern District of California on Monday, December 2, 2024, struck down the 2020 USDA Animal and Plant Health Inspection Service (APHIS) rule codified at 7 C.F.R. § 340 regarding GE plants. The court vacated APHIS’s 2020 rule, formerly known as the SECURE (Sustainable, Ecological, Consistent, Uniform, Responsible, Efficient) rule, which had been adopted to streamline USDA oversight of plants developed using genetic engineering.Summary judgment ruling on December 2, 2024On December 2, 2024, Judge James Donato issued a summary judgment ruling in <a href="https://www.bloomberglaw.com/document/X1M9DNOB0000N" target="_blank">National Family Farm Coalition et al. v. Tom Vilsack et al.</a>, vacating a 2020 update to APHIS’s biotechnology regulations (<a href="https://www.federalregister.gov/documents/2020/05/18/2020-10638/movement-of-certain-genetically-engineered-organisms" target="_blank">7 C.F.R. § 340</a>), which had exempted many GE plants from USDA regulation and streamlined the deregulation process for others. The three main exemptions under the now vacated 2020 rule are codified at 7 CFR § 340.1(b)(1)–(3) and relate to a genetic change caused by cellular repair of a targeted, single double-stranded break; a targeted single base pair substitution; and the introduction of certain types of known sequences from the plant’s gene pool, respectively.The November 2024 updates to the 2020 rule are not explicitly included in the vacaturIn late 2023, <a href="https://www.mofo.com/resources/insights/231115-comment-morphing-us-biotechnology-regs" target="_blank">APHIS proposed five additional exemptions</a> to be incorporated into the 2020 rule. After a review of public comments, <a href="https://www.aphis.usda.gov/news/agency-announcements/aphis-announces-final-notice-additional-exemptions-movement-organisms" target="_blank">two new exemptions were finalized, effective November 13, 2024</a>, and APHIS immediately began to inform developers about their function and effects, including at a November 14, 2024, stakeholder meeting. However, following the December 2 ruling, the new exemptions, which APHIS termed “Additional Modification 1” (AM1) and “Additional Modification 2” (AM2), are now in jeopardy.The November 2024 exemptions are defined as follows:<ul><li>AM1: An indel or contiguous deletion of any size, made at a targeted location, with or without insertion of DNA if generated without using a repair template, or without insertion of DNA if generated using a repair template.</li><li>AM2: A plant with up to twelve (12) modifications, made simultaneously or sequentially, if each modification individually qualifies for exemption and occurs in a different gene.</li></ul>The parties briefed the court regarding these new exemptions prior to the summary judgment ruling. However, the court did not rule on the 2024 updates, and addressed only the 2020 final rule in its December 2 opinion. The parties have been ordered to brief the court by January 13, 2025, as to the impact of the vacatur on the November 2024 exemptions.Thus, as of December 2, the 2020 rule and its exemptions have been vacated. The new exemptions under the 2024 revisions, however, appear to remain in place, at least for now, though it is unclear whether or how APHIS can process requests related to these new exemptions given the status of the 2020 rule.What happens to plants that were approved or exempted under the 2020 rule?APHIS confirmed in a December 4, 2024, <a href="https://www.aphis.usda.gov/news/program-update/aphis-acknowledges-new-court-ruling-vacating-updates-biotechnology-regulations" target="_blank">announcement</a> that “Regulatory Status Review responses, Confirmation Request responses, and active permits that USDA issued prior to December 2, 2024, remain valid.” However, it is uncertain how the ruling will impact both developers who did not engage in a voluntary confirmation of exemption or Regulatory Status Review (RSR) and were proceeding with development under a self-determined exempt status, and developers  with pending confirmation or RSR requests.The ruling does not affect applicable parallel regulatory oversight by the FDA, EPA, or other (e.g., non-APHIS) branches within the USDA.How did this happen?Judge Donato granted partial summary judgment in favor of the plaintiffs, a group of 29 farming and organic non-profit and public-interest groups, finding that APHIS’s adoption of the rule was arbitrary and capricious under the Administrative Procedure Act (APA). The plaintiffs argued in a lawsuit filed on July 6, 2021, that the 2020 rule failed to comply with federal statutes, including the Plant Protection Act (PPA).APHIS adopted the now-vacated rule after nearly 15 years of attempts to update its regulations under part 340 of the PPA for better efficiency in regulation and better reflection of the advances made in gene editing and crop breeding. The 2020 rule introduced regulatory exemptions for certain GE plant modifications, including targeted DNA breaks repaired without a template (part 340(b)(1)), targeted single base pair substitutions (part 340(b)(2)), and insertion of a gene from the plant’s gene pool (part 340(b)(3)). The effect of the rule was to remove certain categories of GE crops from oversight by USDA‑APHIS’s Biotechnology Regulatory Services, including some types of GE plants that could be created by conventional breeding techniques and those that the agency determined do not pose a plant pest risk. This change decreased the regulatory burden and facilitated entry for smaller developers.One issue in the December 2 ruling was how APHIS dealt with “noxious weeds” in the 2020 rule. The 2020 rule did not incorporate APHIS’s authority to regulate noxious weeds into its regulation of GE crops, despite previous proposed rules by APHIS that sought to evaluate GE plants for noxious-weed risk. Citing Transportation Division of the International Association of Sheet Metal, Air, Rail, & Transportation Workers v. Federal Railroad Administration (Transp. Workers), 988 F.3d 1170 (9th Cir. 2021), Judge Donato held that APHIS’s failure to explain the agency’s reversal of its position on additional risk assessments for noxious weeds was arbitrary and capricious.Judge Donato also took issue with the categorical exemptions, which treat the risk of conventionally bred plants as the baseline in determining the scope of regulatory oversight. His reasoning relied heavily on <a href="https://nap.nationalacademies.org/read/10258/chapter/1" target="_blank">a 2002 National Academy of Sciences publication</a> that concluded that risks associated with crop cultivars that could have been developed through conventional breeding “should not be assumed to be acceptable.” Despite APHIS’ position in the briefing that it had carefully assessed the risks of conventionally-bred plants over the past 30 years, Judge Donato categorized the 2020 rule as being in direct conflict with APHIS’s own experts.What’s next?The case may not be immediately appealable as the summary judgment order did not rule on all the plaintiffs’ claims. Plaintiffs also challenged the rule under the Endangered Species Act and the National Environmental Policy Act. The court asked the parties to jointly propose a status conference date to address the remaining claims. USDA could immediately appeal if the district court certifies the summary judgment ruling under Federal Rule of Civil Procedure 54(b), which allows a district court to certify for appeal an order granting summary judgment on an issue that is separate and distinct from other claims in the case. Even if such certification were to occur, expedited review by the Ninth Circuit would not be guaranteed.In the meantime, the vacatur of the 2020 rule reverts the core USDA biotechnology regulations to their pre-2020 framework. Under the pre-2020 system, APHIS regulated GE organisms based on the use of plant pests in the genetic engineering process, rather than the plant pest risks of the final edited products, to which the 2020 rule had shifted focus. Developers could petition APHIS under the old rule for a determination that a GE organism was unlikely to pose a plant pest risk, a process known as a petition for non-regulated status, or obtain an indication of non-regulated status under the legacy “Am I Regulated” (AIR) procedures.APHIS has <a href="https://www.aphis.usda.gov/news/program-update/aphis-acknowledges-new-court-ruling-vacating-updates-biotechnology-regulations" target="_blank">acknowledged</a> the court ruling and plans to provide more detailed guidance to stakeholders in the coming days, but as of this writing, the USDA has not announced any intent or capacity to enforce the old framework.Of note, in March 2018, then-Secretary of Agriculture Sonny Perdue <a href="https://www.usda.gov/media/press-releases/2018/03/28/secretary-perdue-issues-usda-statement-plant-breeding-innovation" target="_blank">stated</a> that the USDA had no plans to regulate plants that could be developed through conventional breeding techniques, provided they were not plant pests or created using plant pests. The incoming Trump administration may seek to retain this approach. However, the vacatur of the 2020 rule’s categorical exemptions undoes much of the groundwork to automatically exempt many such plants from USDA review, assuming the legacy regulations are back in place in the interim.If APHIS moves to propose a new rule to address the court’s ruling, the process would likely be subject to customary procedural requirements, including notice and comment procedures, before finalization.This is a developing story.We are closely monitoring developments in this case and USDA’s forthcoming guidance, and will continue to share updates. Alice Carli, a law clerk in our Los Angeles office, contributed significantly to the drafting of this post. Caressa Tsai, a law clerk in our San Francisco office, also contributed to the drafting of this post.

ward_michael_blog_150x150.png

ward_michael_common_640x280.jpg

ward_michael_heroretina_2700x1160.jpg

ward_michael_mobileretina_750x1040.jpg

ward_michael_social_600x600.jpg

Michael (Mike) Ward is co-chair of the firm's Life Sciences + Healthcare Group, Patent Group, Intellectual Property Group, and Food + Agriculture Group.

Michael Ward Ph.D.

Michael (Mike) Ward is global head of the Life Sciences + Healthcare Group, head of the Patent Group, co-chair of the firm’s Intellectual Property Group, and co-chair of our global Food + Agriculture Group.

Michael Ward

In re Lumber Liquidators Chinese Laminate Litigation

Maxus Energy Corporation

In re Hydroxycut Personal Injury and Class Action Litigation

Los Angeles World Airport (LAWA)

Environmental Law Foundation v. Beech-Nut Nutrition Corp., et al

Fitbit Force Recall 

People of the State of California v. The Coca-Cola Company

Seagate Technology LLC

Clif Bar, Inc.

tarantino_william_blog_150x150.png

tarantino_william_common_640x280.jpg

tarantino_william_heroretina_2700x1160.jpg

tarantino_william_mobileretina_750x1040.jpg

tarantino_william_social_600x600.jpg

Drawing on his considerable experience in environmental health, William (Bill) focuses his practice on environmental and consumer protection law, with an emphasis on climate-related goals and claims, hazardous substances, mass torts, and consumer product safety.

William Tarantino

Drawing on his considerable experience in environmental health, William (Bill) focuses his practice on environmental and consumer protection law, with an emphasis on hazardous substances, mass torts, and consumer product safety.

William F. Tarantino

deboer_krista_blog_150x150.png

deboer_krista_common_640x280.jpg

deboer_krista_heroretina_2700x1160.jpg

deboer_krista_mobileretina_750x1040.jpg

deboer_krista_social_600x600.jpg

Krista deBoer’s practice involves the full range of environmental, climate, and green claims issues. As a partner in MoFo’s Class Actions + Mass Tort practice group, Krista represents clients in environmental and toxic tort litigation, Proposition 65 litigation, and consumer class actions 

Krista S. deBoer

Krista deBoer

freeman-rosenzweig_liz_blog_150x150.png

freeman-rosenzweig_liz_common_640x280.jpg

freeman-rosenzweig_liz_heroretina_2700x1160.jpg

freeman-rosenzweig_liz_mobileretina_750x1040.jpg

freeman-rosenzweig_liz_social_600x600.jpg

Associate

Dr. Liz Freeman Rosenzweig focuses her practice on patent prosecution and intellectual property and regulatory counseling in the areas of life sciences and agricultural biotechnology, including AgTech

Liz Freeman Rosenzweig Ph.D.

Liz Freeman Rosenzweig

Patent Agent

Abby Burrus

tsai_caressa_blog_150x150.png

tsai_caressa_common_640x280.jpg

tsai_caressa_heroretina_2700x1160.jpg

tsai_caressa_mobileretina_750x1040.jpg

tsai_caressa_social_600x600.jpg

Caressa Tsai

190927-dod-promulgates.jpg

New DCMA Defective Pricing Pilot Team Will Possess Audit Resolution Authority

On September 24, 2024, Morrison Foerster hosted another installment of its premier MoForum series at the firm’s San Diego office.Mayor Todd Gloria shared his vision for San Diego’s commitment to the industry. The event featured expert panel discussions on cutting-edge scientific developments, market trends, and technological innovations. Three innovative companies showcased their breakthrough technologies and business models. Renowned keynote speaker Orly Lobel highlighted the transformative power of digital technology in shaping the future of life sciences.Key Takeaways from the Panel’s DiscussionThe ScienceKaren Potter, a partner in MoFo’s Patent Strategy and Prosecution practice, moderated the Science panel. She was joined by Brendan Eckelman (Co-Founder and CSO of Inhibrx Biosciences), Michael Ports (CSO of CARGO Therapeutics), Kit Pogliano (Dean of Biological Sciences, UCSD), and Vaughn Smider (President of Applied Biomedical Science Institute). The discussion highlighted the current and emerging innovation landscape that is driving drug development in life sciences, the role of scientific collaboration in fostering innovation and how it has evolved in San Diego, and the challenges and future outlook for the life sciences sector.The MarketJim Krenn, co-chair of MoFo’s Emerging Companies + Venture Capital Group led the Market panel. He shared the stage with Kim Kamdar (Managing Partner of Medical Excellence Capital), Gavin Liu (Senior Director of Legal Strategic Transactions, Astellas), Niall O’Donnell (Managing Director of RiverVest Venture Partners), and Hunter Reed (Vice President of Alexandria Venture Investments). The panel discussed the current state of the life sciences venture market, including the ongoing challenges many companies raising capital continue to face as well as optimism for the future as interest rates trend downwards.The TechnologyErin Bosman, founder and co-head of MoFo’s Artificial Intelligence Group and chair of MoFo’s Class Actions and Mass Torts Group, led an in-depth dialogue on the Technology panel with Andrés Bratt-Leal (SVP of Research & Development, Aspen Neuroscience), Andrew Burch (President of Nucleic Acid Production, Maravai LifeSciences), Brendan Daly (Senior Innovation & Licensing Manager of San Diego State University), and Doug Komen (CFO of Vektor Medical). They explored the new technologies revolutionizing life sciences, including how these technologies are benefiting companies and customers, the pace of advancement, San Diego’s infrastructure and support of life sciences, and the current challenges posed by these new technologies.ConclusionThe MoForum program provided invaluable insights and sparked meaningful discussions in the life sciences sector. The next installment will take place in Boston in January 2025, with a special focus on women in life sciences. Stay tuned for more details.<div data-reactroot=""><img class="rich-text-embed-image" alt="Life Sciences forum group" src="https://media2.mofo.com/v3/images/blt5775cc69c999c255/blt1ea7645406b44e8e/66fbeee5640f1cc40785775a/241001-life-sciences-blog-1.jpeg?format=auto&amp;quality=60"/></div><div data-reactroot=""><img class="rich-text-embed-image" alt="Table" src="https://media2.mofo.com/v3/images/blt5775cc69c999c255/blt107ba51d021e914b/66fbeefe809624210a7f8127/241001-life-sciences-blog-2.jpeg.jfif?format=auto&amp;quality=60"/></div>

Life Sciences MoForum 2024 | San Diego: The State of the Life Sciences Industry

Fertility Center Litigation

Fitbit

MicroPort

Leading Healthcare, Pharmaceutical, and Medical Device Company

Lethal Injection Matters – Major Pharmaceutical Company

Pain Pump Matters – Large Pharmaceutical Company

Major Technology Company

Leading Chemical Company

Security Device Company

In re Air Crash Near Peixoto de Azevedo, Brazil

bosman_erin_blog_150x150.png

bosman_erin_common_640x280.jpg

bosman_erin_heroretina_2700x1160.jpg

bosman_erin_mobileretina_750x1040.jpg

bosman_erin_social_600x600.jpg

Co-Chair, Litigation Department

Erin Bosman is the global co-chair of Morrison Foerster’s litigation department. Erin is also the founder and co-head of the Artificial Intelligence group and former chair of the Complex Litigation + Advisement practice group. Clients value her business strategy, seeking her comprehensive counsel throughout the product life cycle, especially in high-stakes litigation and product recalls.

Erin M. Bosman

Erin Bosman is the Global Co-Chair of Morrison Foerster’s Litigation Department. Erin is also the founder and co-head of the Artificial Intelligence Group and former chair of the Complex Litigation + Advisement Practice Group. Clients value her business strategy, seeking her comprehensive counsel throughout the product life cycle, especially in high-stakes litigation and product recalls.